MAPKeeper 301
Research type
Research Study
Full title
A Phase 3 Randomized, Open-Label Study of Atebimetinib in Combination with the Modified Gemcitabine and nab-Paclitaxel Regimen Versus the Standard Gemcitabine and nab-Paclitaxel Regimen for the Treatment of Patients with Metastatic Pancreatic Ductal Adenocarcinoma Cancer (MAPKeeper 301)
IRAS ID
1014039
Contact name
Adam Shiell
Contact email
Sponsor organisation
Immuneering Corporation
Clinicaltrials.gov Identifier
Research summary
This study will test Atebimetinib to see if it can treat metastatic (i.e., spreading to other parts of the body) adenocarcinoma (i.e., cancer that begins in gland cells) affecting the small tubes (ducts) of the pancreas (i.e., metastatic pancreatic ductal adenocarcinoma [PDAC]). This type of cancer accounts for more than 90% of all pancreatic tumors and is very difficult to treat. This study will try to find out:
• If Atebimetinib works, i.e., if Atebimetinib, used in combination with the chemotherapy regimen of gemcitabine plus nab-paclitaxel (i.e., one of the usual treatment options for patients with metastatic PDAC), may help people who have never been treated for this condition to live longer.
• How safe Atebimetinib is, i.e., what side effects Atebimetinib causes and how bad they are.
• How specific substances in the blood respond to Atebimetinib, i.e., how these substances (biomarkers) are linked to how well Atebimetinib works or why Atebimetinib may stop working.
This study will assess if the combination of Atebimetinib and the chemotherapy regimen of gemcitabine plus nab-paclitaxel is more efficient compared to gemcitabine plus nab-paclitaxel (control group).
The study will include about 510 participants, aged ≥18 years, diagnosed with metastatic PDAC within 12 weeks prior to enrollment, who are in good physical condition and have at least 1 detectable metastatic spot.
The study contains 3 periods: Screening (can be up to 28 days before the start of treatment), Treatment (participants will regularly come back to the study site to receive IV infusion treatment (gemcitabine plus nab-paclitaxel), and for safety check-ups, blood draws, and other tests), and Follow-up (participants will come back to the study site about 30 days after they finish the study treatment for a safety check).
Participation duration is about 12 months but may be shorter or longer depending upon how the cancer responds to the study treatment.REC name
West Midlands - Edgbaston Research Ethics Committee
REC reference
26/WM/0126
Date of REC Opinion
7 Aug 2026
REC opinion
Further Information Favourable Opinion